South San Francisco, CA Breaking News Headlines Today

News about South San Francisco

Stay current with all the latest and breaking news about South San Francisco, compare headlines and perspectives between news sources on stories happening today. In total, 115 stories have been published about South San Francisco which Ground News has aggregated in the past 3 months.

Local News Publishers

Untracked bias

Suggest a source

Looking for a source we don't already have? Suggest one here.

Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP

South San Francisco · South San Francisco Read Article

Metagenomi (MGX) Projected to Post Quarterly Earnings on Monday

100% Center coverage: 1 sources

South San Francisco · South San Francisco Read Article

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

Coverage: 2 sources

South San Francisco · South San Francisco See the Story

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Roche’s Gazyva/Gazyvaro Significantly Reduces Disease Activity in the Most Common Form of Lupus

Coverage: 2 sources

South San Francisco · South San Francisco See the Story

News about South San Francisco

News about South San Francisco

Local News Publishers Too Big Arrow Icon

Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP

Metagenomi (MGX) Projected to Post Quarterly Earnings on Monday

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

Gyre Therapeutics (GYRE) Expected to Announce Quarterly Earnings on Monday

Lyell Immunopharma (LYEL) Projected to Post Earnings on Tuesday

Bioforcetech, RDD, and Virus Inks Launch Collaboration for Sustainable Textiles

Knott David M Jr Purchases Shares of 30,000 Cytokinetics, Incorporated $CYTK

Analysts Set Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Target Price at $43.20

Veracyte (NASDAQ:VCYT) SVP Annie Mcguire Sells 6,658 Shares

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Roche’s Gazyva/Gazyvaro Significantly Reduces Disease Activity in the Most Common Form of Lupus

Local News Publishers Too Big Arrow Icon

Breaking News Topics Related to South San Francisco

Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP

Metagenomi (MGX) Projected to Post Quarterly Earnings on Monday

Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer

Gyre Therapeutics (GYRE) Expected to Announce Quarterly Earnings on Monday

Lyell Immunopharma (LYEL) Projected to Post Earnings on Tuesday

Bioforcetech, RDD, and Virus Inks Launch Collaboration for Sustainable Textiles

Knott David M Jr Purchases Shares of 30,000 Cytokinetics, Incorporated $CYTK

Analysts Set Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Target Price at $43.20

Veracyte (NASDAQ:VCYT) SVP Annie Mcguire Sells 6,658 Shares

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Roche’s Gazyva/Gazyvaro Significantly Reduces Disease Activity in the Most Common Form of Lupus

Local News Publishers

Local News Publishers